A Late-Stage Vaccine Trial Validates the AI Diagnostics Premium

The setup Wednesday's session highlighted the widening gap between the infrastructure builders and the application layer. While custom silicon deals reshaped the hardware tape, a breakthrough in clinical trials proved that the real leverage is finally moving to AI software and diagnostics.

What's moving

Google is committing up to $12.2 billion to acquire stock in Marvell Technology ($MRVL), pushing the chipmaker up nearly 10% (CNBC). The hyperscaler wants custom silicon to ease its reliance on standard graphics processors. The scale of the commitment shows how urgently cloud providers are trying to verticalize their compute stack.

Nvidia ($NVDA) is stepping beyond hardware sales to act as a broker, directly connecting its GPU buyers with Nordic data center operators (CNBC). Land and cheap power are dictating where artificial intelligence infrastructure gets built. The move highlights that physical footprint constraints now matter just as much as silicon supply.

The United States is preparing to crack down on Chinese technology firms accessing advanced compute through overseas cloud providers (CNBC). Export controls initially targeted physical chips crossing borders. Regulators are learning that compute is a borderless utility, forcing a total rewrite of containment policy.

Featured: Tempus AI ($TEM)

The move Tempus AI added 24.1% to close Wednesday at $61.25. Volume topped 22.4 million shares, which is 4.2 times its 30-day average. The rally pulled the stock cleanly above both its 50-day and 200-day moving averages. Even with the gain, the stock remains 40.7% below its 52-week high and sits roughly flat for the year to date.

What drove it The catalyst came from outside the company's own filings. Late-stage clinical trial data for a cancer vaccine developed by Moderna and Merck cleared a critical hurdle, triggering a sector-wide bid for diagnostic and genomic profiling stocks (Stocktwits). Tempus operates a closed-loop platform that feeds clinical and molecular data into oncology testing. The market is pricing in the assumption that advanced mRNA cancer therapies will require exactly the kind of tumor-sequencing companion diagnostics that Tempus recently pushed through FDA approval. The company estimates that transitioning to unified pricing for its core tests could add roughly $85 million in annual revenues starting next year. This trial data makes that clinical demand look significantly more secure.

The bigger picture Healthcare AI is testing whether software multiples can survive contact with clinical reality. Tempus trades at 8.2 times enterprise value to sales with deeply negative net margins of -17.8%, a valuation profile that demands perfect execution. The company is trying to bridge the gap between biological modeling and enterprise software, turning raw genomic data into a recurring subscription for life sciences research.

This is the hardest part of the commercialization cycle. Investors are currently willing to fund unprofitable growth because the addressable market for precision medicine is entirely inelastic. With 33.3% of the float sold short, Wednesday's sharp price action likely involved forced covering from traders betting against that premium. But this remains a capital-intensive data business masquerading as a pure technology play.

Across the tape

Software found buyers while semiconductors sold off. The $IGV software ETF gained +0.8% while the $SMH semiconductor ETF dropped -1.5%. MicroStrategy ($MSTR) climbed +12.7% on roughly $40 billion in market cap. Nebius Group ($NBIS) shed -9.9%, giving back ground after its recent extreme revenue growth reframed the neocloud trade. Fastly ($FSLY) also lost -11.0%.

Our dashboard reads that hyperscaler aggregate CapEx is running +97.7% above last year (Alpha Galactica), underscoring why infrastructure names remain highly sensitive to any shift in cloud spending. Yields retreated slightly, with the 10-year Treasury settling at 4.65%. Broad indexes ended the session quiet and mixed.

What to watch

• Tempus AI's third-quarter print: The company reports on November 3. The street expects forward guidance on the commercial rollout and pricing transition of its FDA-approved xT companion diagnostic.
• Custom silicon margins: Watch Marvell's upcoming disclosures for the exact margin profile of its $12.2 billion Google arrangement. Custom chips yield structurally lower gross margins than standard merchant silicon.
• Cloud export rules: A regulatory shift restricting Chinese access to overseas cloud compute would immediately force hyperscalers to revise their international revenue projections. Look for draft language from the Commerce Department.